Leaflet ELIGARD 22.5mg powder and solvent for solution for injection
Product code: W67702007 Quantity: 1
Indicated for: prostate cancer; breast cancer; endometriosis
Route of administration: injectable
Substance: leuprorelin (GnRH agonist)
ATC: L02AE02 (Antineoplastic and immunomodulating agents | Hormones and related agents | Gonadotropin releasing hormone analogues)
Leuprorelin is a gonadotropin-releasing hormone (GnRH) agonist used for the treatment of prostate cancer, endometriosis, and precocious puberty. It works by suppressing the production of sex hormones, thereby reducing disease progression.
The medication is administered as a subcutaneous or intramuscular injection, usually once a month or at longer intervals, as directed by a doctor.
Side effects may include hot flashes, decreased libido, fatigue, or bone pain. In rare cases, severe allergic reactions or depression may occur.
Leuprorelin is not recommended for pregnant or breastfeeding women or patients with hypersensitivity to this medication.
General data about ELIGARD 22.5mg
- Substance: leuprorelin
- Date of latest medicines list: 01-06-2026
- Product code: W67702007
- Concentration: 22.5mg
- Pharmaceutical form: powder and solvent for solution for injection
- Quantity: 1
- Product type: Original
- Price: 842.03 RON
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for leuprorelin
Concentrations available for leuprorelin
- 11.25mg
- 22.5mg
- 3.75mg
- 42mg
- 45mg
- 5mg
- 7.5mg